Firstly, in anti-angiogenesis, HAIC directly damages tumor blood vessels by injecting chemotherapeutic drugs through the intrahepatic target artery, while lenvatinib blocks the angiogenesis signaling pathway by inhibiting multiple targets such as vascular endothelial growth factor receptors (VEGFR) (24). This evidence concerns the gene KDR and neoplasm.